SIGHT-DIAGNOSTICS
5.8.2020 15:02:06 CEST | Business Wire | Press release
Sight Diagnostics Ⓡ , the company behind the first FDA-cleared direct-from-fingerstick Complete Blood Count (CBC) analyzer, announced today it has raised $71 million in Series D funding with participation from Koch Disruptive Technologies , Longliv Ventures and OurCrowd . This new round brings Sight’s total funding to more than $124 million and will support the expansion of Sight’s commercial operations globally and advance Sight’s R&D into the detection of additional diseases as well as biomarkers indicating COVID-19 severity.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200805005519/en/
“We firmly believe that Sight’s method of using machine vision to analyze blood is a significant leap forward from the current alternative in healthcare,” said Chase Koch, President of Koch Disruptive Technologies. “Not only is the company bringing truly innovative solutions to the blood diagnostics industry, it is also driving a vision to decentralize information and increase consumer access in healthcare markets across the world.”
Founded in 2011, Sight Diagnostics aims to transform blood testing through its flagship Sight OLOⓇ analyzer which automates the identification and quantification of different blood cell types and anomalies. Sight OLO delivers lab-grade CBC results by measuring 19 different blood parameters in minutes from either a fingerstick or a venous sample. To fuel Sight’s AI-driven method, the company has generated a database of more than half a petabyte of blood imagery, which is used to not only optimize Sight’s current diagnostic algorithms but also to explore new algorithms for the early detection of serious health conditions like sepsis and cancer, as well as blood factors affecting the severity of COVID-19.
“This new investment will enable Sight to substantially expand our U.S. footprint and help usher in a new era of AI-driven diagnostics for a myriad of diseases and health conditions,” said Yossi Pollak, CEO and co-founder of Sight Diagnostics. “We’re glad to have Koch Disruptive Technologies, OurCrowd and other esteemed investors join us on our mission to improve health systems and patient outcomes through developing fast, accurate and less painful diagnostics.”
Since receiving FDA 510(k) clearance* for Sight OLO in late 2019, Sight has continued to expand its global footprint with a specific focus on the US market. Thus far, Sight has secured contractual agreements with healthcare providers and distribution partners to deploy more than 1,000 analyzers over the coming years and will use the funds raised to meet this demand. In parallel, Sight is also working with large pharmaceutical companies, including Pfizer, to provide support for different treatments and therapies. Since early in the pandemic, Sight has deployed its Sight OLO analyzer in frontline healthcare facilities outside of the United States fighting COVID-19, including the globally renowned Sheba Medical Center at Tel Hashomer, Israel.
“At Longliv Ventures, a member of the CK Hutchison Holdings, we look to invest in disruptive companies that aim to dramatically improve lives across the globe,” said Dr. Dan Eldar, the Executive Director of Longliv Ventures. “This is our follow-on investment in Sight Diagnostics, which is now ready to fully commercialize its ground-breaking technology for CBC. We are also excited about the promise of Sight’s computer vision and artificial intelligence capabilities to revolutionize diagnostics in additional areas of hematology and bring about unprecedented rapid and accurate results in a variety of clinical settings”.
“OurCrowd is excited to deepen our relationship with Sight during the company's next phase of growth," said Jon Medved, CEO of OurCrowd. “Sight’s technology has been clinically tested and validated by leading healthcare institutions and we have no doubt it is pioneering the next generation of blood diagnostics."
*In the United States, Sight OLO is 510(k) cleared for use in moderate complexity laboratories; it has not yet been cleared for point-of-care use. Outside of the United States, Sight OLO is CE Marked according to the IVD European directive and approved by the Australian TGA for point of care settings.
About Sight Diagnostics
Founded in 2011, Sight Diagnostics aims to transform health systems and patient outcomes through accurate and pain-free blood diagnostic testing. Sight’s technology, developed over almost a decade of research, represents breakthrough innovations in diagnostic methodology. Sight’s latest blood analyzer, Sight OLO, performs a Complete Blood Count, the most commonly ordered blood test, in minutes. It’s compact: designed to be used in a variety of settings. Sight OLO creates a digital version of a blood sample by capturing more than 1,000 highly detailed images from just two drops of blood obtained from a finger prick or venous sample. These images are then interpreted by proprietary and fully automated AI algorithms. Sight’s first product, Parasight, has been used to detect malaria in almost 1 million tests across 24 countries. The company has rapidly growing offices in the UK, the US and Israel. Learn more at www.SightDX.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200805005519/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom